A PHASE 3 MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ROZANOLIXIZUMAB IN ADULT STUDY PARTICIPANTS WITH PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
- Registry ID
- TP0006
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- UCB INC
- Start date
- 2020-09-30
- Completion date
- 2022-04-22
- Last update
- 2020-04-28
Conditions
- IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
View on source registry